CareRx: Canaccord Raises Price Target To $6.50 Following Financing

Earlier this week, CareRx Corp (TSX: CRRX) closed their C$21.2 million bought deal. Notably, $6.25 million of the proceeds were purchased by Yorkville Asset Management on behalf of existing significant shareholders. Canaccord has since raised their 12-month price target to C$6.50 from C$6 and reiterated their buy rating on the back of the raise.

Tania Gonsalves, Canaccord’s analyst, estimates that with the raise, the company has roughly C$39 million on its balance sheet. She writes, “We believe the current balance sheet is sufficient to fund the SmartMeds Pharmacy Inc. acquisition (pending completion), repay the Yorkville facility next year, and service debt and cash burn until CRRX turns self-funding (expected this year).”

She has also has updated their forecasts to now include the SmartMeds acquisition. SmartMeds is a pharmacy serving over 2,000 people who reside in long-term care, assisted living in Ontario. The purchase price is segmented into three components: $4.0M of upfront cash, ~$0.5M worth of CRRX stock, and an earn-out of up to ~$2.9M in cash payable two years after closing and based on certain milestones.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

She says that the company is expected to add $13 million in revenue and $1.5 million in EBITDA following the close of the transaction. This has increased their EBITDA estimate from C$21.1 million to C$23.3 million.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Kinross Gold: BMO Expects The Sale of Russian Assets

Last week, Kinross Gold Corporation (TSX: K) announced the suspension of its Russian operations. Impacted...

Sunday, March 13, 2022, 11:17:00 AM

BMO Raises Jazz Pharmaceuticals Price Target To US$205

It was announced last week wednesday that Jazz Pharmaceuticals (NASDAQ: JAZZ) would be acquiring GW...

Monday, February 8, 2021, 10:40:00 AM

Dollarama: Canaccord Maintains $57 Price Target

On September 9, Dollarama Inc (TSX: DOL) reported their fiscal second quarter results for the...

Monday, September 13, 2021, 10:52:00 AM

WELL Health: Canaccord Increases Price Target To $8.50 Following Bought Deal

This morning Canaccord Genuity raised their 12-month price target on WELL Health Technologies (TSX: WELL)...

Friday, October 23, 2020, 01:37:00 PM

Antibe: Canaccord Cuts Price Target From $5.00 To $1.20 After Drug Pivot

In early August, Antibe Therapeutics Inc. (TSX: ATE) announced that they have paused their study...

Monday, October 18, 2021, 11:31:00 AM